Business Description
NGM Biopharmaceuticals Inc
NAICS : 325414
SIC : 2836
Compare
Compare
Traded in other countries / regions
0IK.GermanyNGM.USA IPO Date
2019-04-04Description
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 50.42 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.64 | |||||
| Beneish M-Score | -1.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -30.5 | |||||
| 3-Year EBITDA Growth Rate | -34.7 | |||||
| 3-Year EPS without NRI Growth Rate | -33.7 | |||||
| 3-Year FCF Growth Rate | -27.3 | |||||
| 3-Year Book Growth Rate | -13.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.39 | |||||
| 9-Day RSI | 29.81 | |||||
| 14-Day RSI | 33.56 | |||||
| 6-1 Month Momentum % | -67.8 | |||||
| 12-1 Month Momentum % | -68.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.04 | |||||
| Quick Ratio | 6.04 | |||||
| Cash Ratio | 5.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -300.45 | |||||
| Net Margin % | -293.98 | |||||
| ROE % | -54.8 | |||||
| ROA % | -46.67 | |||||
| ROIC % | -401.59 | |||||
| ROC (Joel Greenblatt) % | -1380.87 | |||||
| ROCE % | -55.49 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.58 | |||||
| PB Ratio | 1.22 | |||||
| Price-to-Tangible-Book | 1.22 | |||||
| EV-to-EBIT | -0.27 | |||||
| EV-to-EBITDA | -0.28 | |||||
| EV-to-Revenue | 0.83 | |||||
| EV-to-FCF | -0.31 | |||||
| Price-to-Net-Current-Asset-Value | 1.31 | |||||
| Price-to-Net-Cash | 1.41 | |||||
| Earnings Yield (Greenblatt) % | -370.37 |
How NGM Biopharmaceuticals Inc (NGM) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NGM
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Details
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 55.333 | ||
| EPS (TTM) ($) | -2.05 | ||
| Beta | 1.42 | ||
| Volatility % | 65.46 | ||
| 14-Day RSI | 33.56 | ||
| 14-Day ATR ($) | 0.245752 | ||
| 20-Day SMA ($) | 4.2695 | ||
| 12-1 Month Momentum % | -68.12 | ||
| 52-Week Range ($) | 2.92 - 18.25 | ||
| Shares Outstanding (Mil) | 82.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NGM Biopharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
NGM Biopharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NGM Biopharmaceuticals Inc Frequently Asked Questions
What is NGM Biopharmaceuticals Inc(NGM)'s stock price today?
The current price of NGM is $3.86. The 52 week high of NGM is $18.25 and 52 week low is $2.92.
When is next earnings date of NGM Biopharmaceuticals Inc(NGM)?
The next earnings date of NGM Biopharmaceuticals Inc(NGM) is 2023-05-05 Est..
Does NGM Biopharmaceuticals Inc(NGM) pay dividends? If so, how much?
NGM Biopharmaceuticals Inc(NGM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
